Research location
Gaithersburg
Maryland, United States
Advertisement
Research activity in Gaithersburg
Maryland, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 166 trials and 167 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Gaithersburg
166 linked trials · page 1 of 4Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaNCT07686263 · 2026-08-20 · 1 site observation
RECRUITING
A Study of LTX-001 In Adult Participants With Acute Exacerbation of SchizophreniaNCT07734493 · 2026-08-03 · 1 site observation
RECRUITING
Integrating Free-choice Marketplace, dieTitian coacHing, cultuRally Tailored messagIng to improVE Blood PressureNCT07075588 · 2026-06-25 · 1 site observation
RECRUITING
52-week Open Label Safety-Tolerability StudyNCT07369154 · 2026-04-23 · 1 site observation
RECRUITING
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428 · 2026-04-23 · 1 site observation
RECRUITING
A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647 · 2026-03-31 · 1 site observation
RECRUITING
A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · 2026-02-10 · 1 site observation
RECRUITING
A Study to Evaluate the Effectiveness of DT-101 in Patients With DepressionNCT07300969 · 2025-12-16 · 1 site observation
RECRUITING
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229 · 2025-12-02 · 1 site observation
RECRUITING
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaNCT07191483 · 2025-08-27 · 1 site observation
RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaNCT07145918 · 2025-08-04 · 1 site observation
RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874 · 2025-07-11 · 1 site observation
RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)NCT07011732 · 2025-07-10 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06963021 · 2025-05-30 · 1 site observation
RECRUITING
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22 · 1 site observation
RECRUITING
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT06963034 · 2025-05-08 · 1 site observation
RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401 · 2025-04-16 · 1 site observation
RECRUITING
ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416 · 2024-10-02 · 1 site observation
RECRUITING
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)NCT06031688 · 2024-08-08 · 1 site observation
RECRUITING
Study of ALTO-101 in Patients With SchizophreniaNCT06502964 · 2024-06-11 · 1 site observation
RECRUITING
ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 · 2023-11-14 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05 · 1 site observation
RECRUITING
Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335 · 2022-01-24 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderNCT07772531 · 2026-10-30 · 1 site observation
NOT_YET_RECRUITING
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850 · 2025-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe ExacerbationNCT07414134 · 2025-10-31 · 1 site observation
COMPLETED
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With SchizophreniaNCT06924255 · 2025-04-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMNCT06897202 · 2025-03-14 · 1 site observation
COMPLETED
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · 2025-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of SchizophreniaNCT06791122 · 2025-01-23 · 1 site observation
COMPLETED
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderNCT06785012 · 2024-12-26 · 1 site observation
COMPLETED
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)NCT06423781 · 2024-08-01 · 1 site observation
COMPLETED
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsNCT06494397 · 2024-07-11 · 1 site observation
COMPLETED
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With AticaprantNCT06514742 · 2024-06-26 · 1 site observation
TERMINATED
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionNCT06419608 · 2024-05-28 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderNCT06267846 · 2024-03-20 · 1 site observation
COMPLETED
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · 2024-03-18 · 1 site observation
COMPLETED
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108 · 2023-11-29 · 1 site observation
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNCT06107803 · 2023-10-13 · 1 site observation
COMPLETED
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationNCT05741528 · 2023-03-31 · 1 site observation
COMPLETED
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN StudyNCT05568472 · 2023-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · 2023-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SchizophreniaNCT05693935 · 2023-01-24 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.